Synapse - Immune biomarkers and response to checkpoint inhibition of BRAF(V600) and BRAF non-V600 altered lung cancers

Immune biomarkers and response to checkpoint inhibition of BRAF(V600) and BRAF non-V600 altered lung cancers Journal Article

Authors:	Murciano-Goroff, Y. R.; Pak, T.; Mondaca, S.; Flynn, J. R.; Montecalvo, J.; Rekhtman, N.; Halpenny, D.; Plodkowski, A. J.; Wu, S. L.; Kris, M. G.; Paik, P. K.; Riely, G. J.; Yu, H. A.; Rudin, C. M.; Hellmann, M. D.; Land, J. D.; Buie, L. W.; Heller, G.; Lito, P.; Yaeger, R.; Drilon, A.; Liu, D.; Li, B. T.; Offin, M.
Article Title:	Immune biomarkers and response to checkpoint inhibition of BRAF(V600) and BRAF non-V600 altered lung cancers
Abstract:	Background While 2-4% of lung cancers possess alterations in BRAF, little is known about the immune responsiveness of these tumours. Methods Clinical and genomic data were collected from 5945 patients with lung cancers whose tumours underwent next-generation sequencing between 2015 and 2018. Patients were followed through 2020. Results In total, 127 patients with metastatic BRAF-altered lung cancers were identified: 29 tumours had Class I mutations, 59 had Class II/III alterations, and 39 had variants of unknown significance (VUS). Tumour mutation burden was higher in Class II/III than Class I-altered tumours (8.8 mutations/Mb versus 4.9, P < 0.001), but this difference was diminished when stratified by smoking status. The overall response rate to immune checkpoint inhibitors (ICI) was 9% in Class I-altered tumours and 26% in Class II/III (P = 0.25), with median time on treatment of 1.9 months in both groups. Among patients with Class I-III-altered tumours, 36-month HR for death in those who ever versus never received ICI was 1.82 (1.17-6.11). Nine patients were on ICI for >2 years (two with Class I mutations, two with Class II/III alterations, and five with VUS). Conclusions A subset of patients with BRAF-altered lung cancers achieved durable disease control on ICI. However, collectively no significant clinical benefit was seen.
Keywords:	mutations; clinicopathological features; adenocarcinomas; multicenter; landscape; clinical characteristics; open-label; pembrolizumab; dabrafenib plus trametinib; mutant nsclc
Journal Title:	British Journal of Cancer
Volume:	126
Issue:	6
ISSN:	0007-0920
Publisher:	Nature Publishing Group
Date Published:	2022-04-01
Start Page:	889
End Page:	898
Language:	English
ACCESSION:	WOS:000735340000002
DOI:	10.1038/s41416-021-01679-1
PROVIDER:	wos
PMCID:	PMC8927094
PUBMED:	34963703
Notes:	Article -- Source: Wos